Close
ACHEMA MIDDLE EAST 2026
5th LNP Formulation & Process Development Summit

Research & Development

Otsuka Holdings Announces Collaboration with ReCor Medical for Commercialization of ReCor Medical’s Ultrasound Renal Denervation Technology in Asia

Research & Development
Otsuka Holdings Co Ltd announced the signing of a development and commercialization agreement with ReCor Medical Inc. (“ReCor”), together with an additional investment. As...

Chugai Pharmaceutical Co Ltd announced Efficacy of Actemra Subcutaneous Injection Confirmed in Dose Interval Reduction Study in Patients with Rheumatoid Arthritis

Asia
Chugai Pharmaceutical announced that "Actemra® Subcutaneous Injection" , the humanized antihuman IL-6 receptor monoclonal antibody, successfully met the primary endpoint in a dose interval...

Pfizer Announces Results From Two Phase 3 TRUMENBA Studies At The European Society For Paediatric Infectious Diseases Meeting

Research & Development
  Pfizer Inc announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal Group B Vaccine) against invasive meningococcal B (MnB)...

Biogen and Abbvie Receive Positive Opinion From The CHMP on ZINBRYTA™ (daclizumab) For Treatment Of Multiple Sclerosis

Research & Development
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of...

Inovio Signs Collaborative Research Agreements

Research & Development
Inovio Signs Collaborative Research Agreements With Wistar Institute for DNA-based Immunotherapies and VaccinesNew Agreement Follows Dr. David B. Weiner’s Move to Wistar from...

AstraZeneca’s potential medicine for neuromyelitis optica receives FDA Orphan Drug Designation

Research & Development
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Orphan...

Orexigen and Takeda Jointly Announce Orexigen’s Acquisition of All Rights to CONTRAVE® in United States

Research & Development
Acquisition provides Orexigen ownership of CONTRAVE in nearly all major global markets Takeda Moves to Strengthen Focus on Recent Launches Orexigen Therapeutics, Inc. (Nasdaq:...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

Whitepapers 0
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

Whitepapers 0
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Whitepapers 0
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...

About us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and
comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector. . . Read More

Resources

Advertise

Subscribe

Copyright © Value Media Group 2026. All rights reserved.